Semaglutide: What Clinical Research Reveals About Weight Loss, Heart Health, and Long-Term Treatment

A New Chapter in Medical Weight Management

Semaglutide, originally developed for type 2 diabetes, has demonstrated substantial effects on weight management and certain cardiovascular outcomes. Clinical trials also clarify its limitations, adverse effects, and the importance of long-term care.

How Semaglutide Works

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It acts on pathways involved in appetite, satiety, glucose regulation, and gastric emptying. Wegovy and Ozempic contain semaglutide but have different approved indications and dosing.

Weight Loss: The STEP 1 Trial

In the randomized STEP 1 trial of 1,961 adults with overweight or obesity without diabetes, participants receiving weekly semaglutide 2.4 mg plus lifestyle intervention lost an average 14.9% of starting weight after 68 weeks, versus 2.4% with placebo plus lifestyle intervention. Results vary by individual. [1]

Longer-Term Results: STEP 5

In STEP 5, a 104-week randomized trial of 304 adults, average weight loss was 15.2% with semaglutide versus 2.6% with placebo. This demonstrates sustained weight reduction during continued treatment, though it does not guarantee outcomes for individual patients. [2]

Cardiovascular Findings: SELECT

The SELECT trial followed 17,604 adults with overweight or obesity and established cardiovascular disease, but without diabetes. Semaglutide 2.4 mg reduced the relative risk of the combined outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% compared with placebo. This finding applies to the population studied, not everyone considering weight management. [3]

What Happens After Stopping Treatment?

In an extension of STEP 1, participants who discontinued semaglutide and structured lifestyle intervention regained, on average, about two-thirds of their prior weight loss over the following year. This supports the importance of long-term management planning. [4]

Safety and Limitations

Common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Other important warnings and precautions include pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycemia with certain diabetes medications, and allergic reactions. Semaglutide has a boxed warning for thyroid C-cell tumors observed in rodents and is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or MEN2. A clinician should review individual risks, other medicines, and the current product labeling. [5]

Research on approved formulations and studied doses should not automatically be generalized to unapproved or compounded versions. Trial populations and the clinical follow-up they received may differ from everyday practice.

Conclusion

Semaglutide has strong clinical evidence for meaningful weight loss in appropriately selected patients, as well as cardiovascular risk reduction in certain higher-risk adults. Its benefits must be weighed against safety considerations, and discontinuation may be followed by substantial weight regain. Treatment decisions belong in an individualized medical discussion.